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Background: Irisin, an exercise induced myokine, has broad implications for metabolism and energy homeostasis.
Available evidence about the association of serum irisin with chronic kidney disease (CKD) is limited.
Methods: Cross-sectional data on socio-demographic, lifestyle, clinical characteristics and serum irisin were collected
for 1,115 community-living obese Chinese adults (waist circumference≥ 90 cm for men and≥ 80 cm for women). CKD
was defined as estimated glomerular filtration rate less than 60 ml/min per 1.73 m2 and/or the presence of albuminuria.
Associations of serum irisin and body composition measurements with CKD were analyzed using multivariable logistic
regression.
Results: The overall prevalence of CKD were 23.1% (26.6% in females and 15.5% in males, p < 0.001). Subjects within
quartile 4 group of serum irisin had significantly the lowest prevalence of CKD (22.9%, 22.2%, 28.7% and 18.7% for
quartile 1–4 groups, respectively, p = 0.046). With adjustment for potential confounders, compared with those within
quartile 1 group of serum irisin, subjects within quartile 4 group showed significantly decreased risk of CKD and
marginally decreased risk of albuminuria, with the adjusted odds ratios (ORs, 95% CI) of 0.572 (0.353-0.927, p = 0.023)
and 0.611 (0.373-1.000, p = 0.050), respectively. As for body composition measurements, only body fat percentage was
significantly associated with both albuminuira and CKD, with ORs (95% CI) of 1.046 (1.002-1.092, p = 0.039) and 1.049
(1.006-1.093, p = 0.025), respectively. No statistically significant interaction effect between serum irisin and body
composition measurements on CKD was found.
Conclusions: Our results imply that high serum irisin level was associated with reduced risk of CKD, and should be
confirmed in future studies. Furthermore, adiposity per se, rather than body weight or body shape, is independently
associated with increased risk of CKD. Future studies should examine whether decreasing body fat percentage may
prevent or slow CKD.
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Chronic kidney disease (CKD), typically defined by re-
duced estimated glomerular filtration rate (eGFR) and/or
albuminuria, is considered as a major public health
problem because of its increasing prevalence worldwide
and its independent association with all-cause mortality
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unless otherwise stated.stage renal disease [1-4]. The prevalence rate of CKD in
China is about 10% [5-7]. Understanding the risk factors
of CKD and identifying individuals with specific risk fac-
tors remain important prevention strategies.
Obesity has become the largest epidemic of modern
time and is associated with an increased risk of insulin
resistance, metabolic syndrome, type 2 diabetes, hyper-
tension, cardiovascular disease, cancer and CKD [8,9].
Exercise has long been consistently shown to be effective
in improving body composition and metabolic health
[10,11], although the underlying mechanisms for thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Boström recently found that irisin, a putative exercise
induced myokine, drives brown-fat-like conversion of
white adipose tissues, and has broad implications for
metabolism and energy homeostasis [12,13]. Irisin is se-
creted by myocytes and proteolytically processed from the
product of the FNDC5 gene prior to being released into
the circulation and regulated by PPAR-γ coactivator-1
(PGC1)-α. In mice, FNDC5 expression in muscle and cir-
culating irisin increased in response to overexpression of
PGC1-α as well as 3 weeks of aerobic exercise-training
[12]. Huh also found circulating irisin levels were signifi-
cantly upregulated 30 min after acute exercise [14]. Be-
cause low serum irisin was found to be associated with
type 2 diabetes and obesity [15-17] and both these two
conditions were independent risk factors of CKD [1], it is
suspected that CKD patients have altered irisin levels.
However, evidence on the association between serum iri-
sin and CKD is limited with complicated results [18-20],
and more studies are awaited to validate this association.
Most previous studies have found that obesity is inde-
pendently associated with increased risk of CKD, and
body mass index (BMI) has been widely used as the
index of obesity in these studies [1-3,5-7]. However, nu-
merous studies have reported that BMI and other mea-
sures of adiposity, such as waist circumference, body fat
percentage, have been shown to have different associa-
tions with various health conditions [21-23]. Recent
studies show that irisin is not only a myokine but also
an adipokine [24,25]. Therefore, more studies are war-
ranted to test the independent association of serum iri-
sin concentration and body composition measurements
with CKD in different populations.
In the present cross-sectional study of 1,115 community-
living healthy obese Chinese adults, we aimed to determine
the independent association of serum irisin concentration
and different body composition measurements with CKD.
Furthermore, potential interaction effects between serum




Obese adults were local residents aged 40 years or older
living in the Lianqian community, Xiamen, China, and
were screened with physical examination from April
2011 to August 2011. Subject sampling, recruitment and
evaluation have been described earlier [26,27]. Briefly, a
total of 1,523 subjects with central obesity (waist circum-
ference greater than 90 cm for men and 80 cm for women)
were included. Of them, 1,115 (73.2%) subjects with the
complete data on the entire examination were left for fur-
ther analysis. The study was approved by the Human Re-
search Ethics Committee of the First Affiliated Hospital ofXiamen University (Xiamen, China). Written informed
consent was obtained from each participant.
Measurements
Screening protocol and evaluation criteria were de-
scribed elsewhere [26,27]. Staff members participating in
this study are doctors and medical students, who re-
ceived intensive training for epidemiologic screening
methods. Data were collected at community health ser-
vice centers. Standard questionnaires were used during
face-to-face interview to collect socio-demographic sta-
tus, lifestyle habits (including physical activities using
the International Physical Activity Questionnaire –Long
form), present and previous health history and medica-
tions. Subjects, who had cancer, current treatment with
systemic corticosteroids, biliary obstructive diseases, acute
or chronic virus hepatitis, drug-induced liver diseases,
total parenteral nutrition, autoimmune hepatitis, Wilson’s
disease, known hyperthyroidism or hypothyroidism, were
excluded.
Anthropometric and clinical measurements
Anthropometric measurements were obtained using stand-
ard protocols and techniques. After removal of shoes and
heavy clothing, each subject underwent weight, height and
waist circumference measurements, using a calibrated
scale. Body mass index (BMI) was calculated as weight in
kilograms divided by height in squared meters as a meas-
ure of general obesity. Waist circumference was measured
at the midpoint between the inferior costal margin and the
superior border of the iliac crest on the midaxillary line.
Body fat were quantified with the Hologic whole body
DXA systems (Hologic Inc., Bedford, MA). Arterial blood
pressure was measured with a mercury sphygmomanom-
eter after sitting for at least 15 minutes. Blood pressure
measurements were taken according to the Joint National
Committee VII criteria (JNC VII) [28]. Three readings
were taken at 5-min intervals. The mean of the three mea-
surements was recorded.
Biochemical measurements
75-g oral glucose tolerance test and blood biochemical
measurements were conducted for each subject. All blood
samples were obtained after 12-hour fasting. Blood and
urine samples were refrigerated at −20°C, transferred and
tested in the central laboratory of the First Affiliated Hos-
pital, Xiamen University. Plasma glucose, liver enzyme
levels, and serum lipid profiles, including triglyceride
(TG), total cholesterol (TC), and high-density lipoprotein
cholesterol (HDL-C) were determined on a HITACHI
7450 analyzer (HITACHI, Tokyo, Japan). Low-density lipo-
protein cholesterol (LDL-C) was calculated by Friedewald’s
formula. Fasting plasma glucose concentration (FPG) and
2-hour plasma glucose concentration (2hPG) were
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concentration was measured by electrochemiluminiscence
immunoassay (Roche Elecsys Insulin Test, Roche Diagnos-
tics, Mannheim, Germany). HOMA-insulin resistance
(HOMA-IR) was calculated by fasting serum insulin (Flns,
mU/ml) *fasting blood glucose (FPG, mmol/L)/22.5. Raised
fasting plasma glucose (FPG) was defined as FPG ≥
100 mg/dL (5.6 mmol/L) or previously diagnosed type 2
diabetes. Serum uric acid was measured by the auto-
analyzer (COBAS INTEGRA 400 plus, Roche, Basel,
Switzerland); and hyperuricemia was defined as the serum
uric acid level >7.0 mg/dL in males and >6.0 mg/dL in
females.
Serum irisin measurement
Serum irisin concentration was measured using the
enzyme-linked immunosorbent assay (ELISA) kits (Aviscera
Biosciences, Santa Clara, CA). The assay was proven to be
highly sensitive to human irisin [26,27]. The sensitivity of
the assay was 0.2 ng/ml and the linear range of the standard
was 5 to 500 ng/ml. The intra- and inter- assay variations
were both less than 10%.
Definition of chronic kidney disease
Serum creatinine (Scr) was measured by Jaffe’s kinetic
method and was standardized at the central laboratory
to a national reference. Estimated glomerular filtration
rate (eGFR) was calculated using the following estimat-
ing equation which was developed by modifying the
Modification of Diet in Renal Disease (MDRD) equation
based on the data from Chinese CKD patients [29,30].
eGFR mL=min=1:73 m2
  ¼ 175  Scr mg=dLð Þ−1:234
 age yearð Þ−0:179 female  0:79½ 
Reduced renal function was defined as an eGFR <60 mL/
min/1.73 m2.
Urinary creatinine and albumin were measured on a
morning urine sample using an automatic analyzer
(COBAS INTEGRA 400 plus, Roche, Basel, Switzerland).
Creatinine was measured using the same method as that
for serum creatinine. Urinary albumin was measured by
immunoturbidimetric method. Urinary albumin-to-
creatinine ratio (ACR, milligram per gram) was calcu-
lated. Microalbuminuria and macroalbuminuria were de-
fined according to the guideline of American Diabetes
Association as an increase in ACR between 30 and
299 mg/g and 300 mg/g or over, respectively. The term
of albuminuria was used to describe the presence of ei-
ther microalbuminuria or macroalbuminuria. CKD was
defined as the presence of either a reduced glomerular
filtration rate or albuminuria [1].Statistical analysis
Data were presented as the mean ± standard deviation or
median (interquartile range) for continuous variables or
number and percentage for categorical variables. Irisin
was also log-transformed to obtain better approximation
of normal distribution. Differences between subjects
were analyzed using one way ANOVA or Mann–Whit-
ney U test for continuous variables and chi-square test
for categorical variables.
Multivariable logistic regression was used to calculate
adjusted odds ratios (OR) and 95% confidence intervals
(CI) of serum irisin concentration and body composition
measurements for reduced renal function, albuminuria
and CKD in different models with adjustment for poten-
tial confounders. In model 1, age and sex were adjusted
for; in model 2, educational level, smoking and drinking
habits and physical activity were further adjusted for; in
model 3, SBP, DBP, serum globulin, hyperuricemia, TG,
LDL and FPG. Different measurements of body compos-
ition, such as BMI, waist circumference, body fat mass
and body fat percentage, were tested in the multivariable
logistic regression models separately. In each of the mul-
tivariable logistic regression models, interaction effects
among serum irisin, body composition measurements and
diabetes status were tested separately; and stratified ana-
lysis by diabetes status was conducted as well. P <0.05 was
considered statistically significant. All statistical analyses
were performed using R version 3.1.0 [31].
Results
Of the 1,115 participants, 766 (68.7%) were female. The
mean age (±SD) of women and men were 53.1 (±7.1)
years and 53.3 (±7.6) years (p = 0.702), respectively. Fe-
males had higher prevalence of CKD (26.6% vs. 15.5%,
p < 0.001) and albuminuria (23.8% vs. 12.6%, p < 0.001),
but showed similar prevalence of reduced renal function
(3.8% vs. 3.2%, p = 0.598), when compared with males.
The total prevalence rates (95% confidence interval (CI))
of CKD were 26.6% (23.2%-29.4%) in females and 15.5%
(11.8%-19.2%, p < 0.001) in males, respectively.
Demographic and clinical characteristics stratified by
reduced renal function, albuminuria and CKD
Differences in demographics, life style habits, body com-
position measurements and clinical characteristics of
subjects stratified by reduced renal function, albumin-
uria and CKD are presented in Table 1. Older age was
significantly associated with higher prevalence of re-
duced renal function, albuminuria and CKD. Generally,
subjects with albuminuria and CKD showed significantly
higher levels of systolic BP, diastolic BP, serum globulin,
TG, total cholesterol, LDL, fasting glucose, fasting insu-
lin, HOMA-IR and HbA1c than their controls. Patients
with reduced renal function showed significantly higher
Table 1 Demographic, lifestyle and clinical characteristics of subjects by reduced renal function, albuminuira and CKD
Reduced renal function Albuminuira CKD
Variables No Yes P value No Yes P value No Yes P value
Demographics
N (%) 1075 (96.4%) 40 (3.6%) 889 (79.7%) 226 (20.3%) 857 (76.9%) 258 (23.1%)
Sex 0.6 <0.001‡ <0.001‡
Female (n, %) 737 (68.6%) 29 (72.5%) 584 (65.7%) 182 (80.5%) 562 (65.6%) 204 (79.1%)
Male (n, %) 338 (31.4%) 11 (27.5%) 305 (34.3%) 44 (19.5%) 295 (34.4%) 54 (20.9%)




Illiteracy 292 (27.2%) 10 (25.0%) 227 (25.5%) 75 (33.2%) 221 (25.8%) 81 (31.4%)
Elementary school 324 (30.1%) 6 (15.0%) 263 (29.6%) 67 (29.7%) 257 (30.0%) 73 (28.3%)
Middle school 243 (22.6%) 13 (32.5%) 215 (24.2%) 41 (18.1%) 204 (23.8%) 52 (20.2%)
High school 136 (12.7%) 6 (15.0%) 113 (12.7%) 29 (12.8%) 108 (12.6%) 34 (13.2%)
College or above 80 (7.4%) 5 (12.5%) 71 (8.0%) 14 (6.2%) 67 (7.8%) 18 (7.0%)
Life style
Ever smoking (n, %) 289 (26.9%) 6 (15.0%) 0.1 264 (29.7%) 31 (13.7%) <0.001‡ 258 (30.1%) 37 (14.3%) <0.001‡
Ever drinking (n, %) 128 (11.9%) 2 (5.0%) 0.2 114 (12.8%) 16 (7.1%) <0.001‡ 112 (13.1%) 18 (7.0%) <0.001‡
Physical activity
(MET-h/week)
84.4 (54.4, 148.4) 84.0 (28.0, 140.0) 0.1 84.0 (46.2, 140.0) 102.0 (56.0, 163.8) 0.005† 84.0 (46.2, 141.8) 101.4 (56.0, 158.2) 0.027*
Body composition indices
BMI (kg/m2) 27.4 ± 3.1 27.9 ± 2.6 0.4 27.3 ± 2.9 28.1 ± 3.4 <0.001‡ 27.3 ± 3.0 28.0 ± 3.3 <0.001‡
Waist circumference
(cm)
93.6 ± 7.1 93.7 ± 5.5 1.0 93.4 ± 6.9 94.6 ± 7.6 0.023* 93.4 ± 7.0 94.3 ± 7.3 0.1
Waist hip ratio 0.937 ± 0.050 0.938 ± 0.049 0.8 0.936 ± 0.050 0.939 ± 0.047 0.5 0.936 ± 0.050 0.938 ± 0.047 0.6
Body fat mass (kg) 23.8 ± 5.3 25.8 ± 6.1 0.021* 23.5 ± 5.3 25.2 ± 5.4 <0.001‡ 23.5 ± 5.2 25.2 ± 5.4 <0.001‡
Body fat rate (%) 34.7 ± 6.7 36.5 ± 6.9 0.1 34.1 ± 6.7 37.1 ± 6.4 <0.001‡ 34.0 ± 6.7 36.9 ± 6.5 <0.001‡
Body fat free
weight (kg)
45.9 ± 8.5 44.8 ± 6.8 0.4 46.4 ± 8.6 43.9 ± 7.5 <0.001‡ 46.4 ± 8.6 44.0 ± 7.5 <0.001‡




133.7 ± 17.7 140.5 ± 20.1 0.019* 131.5 ± 16.4 143.6 ± 20.1 <0.001‡ 131.2 ± 16.2 143.2 ± 19.9 <0.001‡
Diastolic blood
pressure (mmHg)












Table 1 Demographic, lifestyle and clinical characteristics of subjects by reduced renal function, albuminuira and CKD (Continued)
Serum albumin
(g/L)
49.1 ± 2.4 48.4 ± 3.0 0.1 49.0 ± 2.4 49.2 ± 2.4 0.4 49.0 ± 2.4 49.1 ± 2.5 0.6
Serum glubulin
(g/L)
25.9 ± 3.4 27.4 ± 3.1 0.009† 25.8 ± 3.4 26.9 ± 3.4 <0.001‡ 25.7 ± 3.4 26.9 ± 3.3 <0.001‡
Triglyceride
(mmol/L)
1.88 ± 1.29 1.83 ± 0.97 0.8 1.82 ± 1.25 2.10 ± 1.38 0.003† 1.81 ± 1.26 2.06 ± 1.34 0.009†
Total cholesterol
(mmol/L)
5.87 ± 1.09 5.88 ± 1.13 0.9 5.81 ± 1.07 6.09 ± 1.14 <0.001‡ 5.81 ± 1.06 6.06 ± 1.14 <0.001‡
HDL-cholesterol
(mmol/L)
1.37 ± 0.30 1.35 ± 0.26 0.7 1.37 ± 0.30 1.36 ± 0.28 0.6 1.37 ± 0.30 1.36 ± 0.28 0.6
LDL-cholesterol
(mmol/L)
3.65 ± 1.02 3.76 ± 0.93 0.5 3.62 ± 1.00 3.78 ± 1.04 0.038* 3.62 ± 1.00 3.78 ± 1.02 0.024*
Fasting glucose
(mmol/L)
6.17 ± 1.77 5.84 ± 0.87 0.2 6.05 ± 1.51 6.60 ± 2.44 <0.001‡ 6.06 ± 1.53 6.49 ± 2.31 <0.001‡
Glucose 120 min
OGTT (mmol/L)
9.06 ± 4.13 8.85 ± 3.32 0.8 8.68 ± 3.80 10.52 ± 4.86 <0.001‡ 8.69 ± 3.84 10.26 ± 4.68 <0.001‡
Fasting insulin
(mIU/L)
12.7 ± 6.8 13.9 ± 6.1 0.3 12.3 ± 6.2 14.6 ± 8.3 <0.001‡ 12.2 ± 6.2 14.5 ± 8.1 <0.001‡
HOMA-IR (*10-6
mol*IU*L-2)
3.54 ± 2.37 3.62 ± 1.72 0.8 3.36 ± 2.06 4.28 ± 3.14 <0.001‡ 3.34 ± 2.07 4.21 ± 3.01 <0.001‡
HbA1c 6.21 ± 1.05 6.21 ± 0.65 1.0 6.15 ± 0.94 6.45 ± 1.34 <0.001‡ 6.15 ± 0.95 6.41 ± 1.27 <0.001‡
Blood uric
acid (mol/L)
360.2 ± 89.6 424.1 ± 119.9 <0.001‡ 363.7 ± 90.1 357.5 ± 97.3 0.4 361.4 ± 87.9 366.0 ± 102.9 0.5
Hyperuricemia,
(n (%))
404 (37.6%) 26 (65.0%) <0.001‡ 331 (37.2%) 99 (43.8%) 0.1 310 (36.2%) 120 (46.5%) 0.003†
Irisin (ng/mL) 7.29 (2.72, 14.82) 6.46 (2.84, 11.05) 0.5 7.18 (2.76, 15.15) 7.74 (2.58, 13.30) 0.8 7.18 (2.74, 15.23) 7.53 (2.74, 13.13) 0.6
Irisin-log transformed
(ng/mL)§
1.30 ± 1.24 1.28 ± 1.04 1.0 1.31 ± 1.22 1.23 ± 1.29 0.6 1.31 ± 1.23 1.24 ± 1.25 0.6
*p < 0.05, †p < 0.01, ‡p < 0.001.
§Irisin was log-transformed to obtain better approximation of normal distribution.
All percentages are column percentage; except for percentages, all values are mean ± s.d. or median(25th, 75th) for non-normal distribution data.
Abbreviations: A/G ratio, albumin/globulin ratio, BMI body mass index, CKD chornic kidney disease, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein cholesterol, HOMA-IR homeostasis model












Yang et al. BMC Nephrology  (2015) 16:16 Page 6 of 11systolic BP, serum globulin and blood uric acid than
their controls. As for body composition measurements,
subjects with albuminuria and CKD showed significantly
higher levels of BMI, waist circumference, body fat mass
and body fat percentage but lower levels of muscle mass
and body fat free mass than their controls. There was no
significant difference in serum irisin levels (neither the
original serum irisin values or the corresponding log-
transformed values) for subjects with reduced renal
function, albuminuira and total CKD compared with
their controls.
Demographic and clinical characteristics stratified by
quartiles of serum irisin
Table 2 shows that subjects were divided into four
groups according to quartiles of serum irisin levels (me-
dian (interquartile range): 0.13(0.02 – 1.56), 4.73(3.83 –
5.97), 10.38(8.67 – 12.17) and 23.05(17.73 – 31.28) for
quartile 1–4, respectively). With increasing levels of
serum irisin, subjects had significantly lower levels of
waist hip ratio and muscle mass but higher levels of
serum globulin and LDL and more likely to be females.
There were no statistically significant difference in the
levels of systolic BP, diastolic BP, BMI, waist circumfer-
ence, body fat percentage, TG, TC, HDL, FPG, fasting
insulin, HOMA-IR and HbA1c among these four
groups. Subjects within the quartile 4 group of serum
irisin had significantly the lowest prevalence rate of
CKD (22.9%, 22.2%, 28.7% and 18.7% for quartile 1–4
groups, respectively, p = 0.046); and they also showed
the lowest prevalence rate of albuminuira, although the
difference was not statistically significant (20.4%, 18.6%,
25.1% and 16.9% for quartile 1–4 groups, respectively,
p = 0.093).
Associations of serum irisin and body composition
measurements with reduced renal function, albuminuira
and CKD
Table 3 shows the adjusted odds ratios (ORs) with asso-
ciated 95% confidence interval (CI) of serum irisin and
body composition measurements for reduced renal func-
tion, albuminuria and CKD. In model 1 with adjustment
for sex and age, increasing levels of body composition
measurements, such as BMI, waist circumference, body
fat mass and body fat percentage, were all significantly
associated with increased risks of albuminuria and CKD.
Body fat mass and body fat percentage were also signifi-
cantly associated with increased risk of reduced renal
function. Waist hip ratio, body fat free weight and
muscle mass were not significantly associated with re-
duced renal function, albuminuria and CKD (data not
shown). Serum irisin concentration (both the log-
transformed value and the categorical values) was not
significantly associated with reduced renal function,albuminuria or CKD. In model 2 (additional adjustments
for educational level, smoking and drinking habits and
physical activity), the results for body composition mea-
surements were quite similar to those in model 1. How-
ever, subjects with the highest serum irisin (quartile 4
group) showed significantly decreased risk of CKD com-
pared with those with the lowest (quartile 1 group), with
the adjusted OR (95% CI) of 0.620 (0.393-0.980, p =
0.041).
The last full model (model 3) was further adjusted for
SBP, DBP, serum globulin, hyperuricemia, TG, LDL and
FPG. As for body composition measurements, increasing
body fat percentage was significantly associated with in-
creased risks of both albuminuira and CKD, and increas-
ing body fat mass was also significantly associated with
increased risk of CKD. Other body composition mea-
surements, such as BMI and waist circumference, were
not significantly associated with reduced renal function,
albuminuria or CKD. Compared with those with the
lowest serum irisin (quartile 1 group), subjects with the
highest (quartile 4 group) showed significantly decreased
risk of CKD and marginally decreased risk of albuminuria,
with the adjusted ORs (95% CI) of 0.572 (0.353-0.927, p =
0.023) and 0.611 (0.373-1.000, p = 0.050), respectively. We
also used log transformation of eGFR and ACR for linear
regression analysis, but the associations of serum irisin
with eGFR and ACR were not statistically significant (data
not shown).
No statistically significant interaction effect between
serum irisin and body composition measurements on
CKD was found. Furthermore, stratified analysis by dia-
betes mellitus showed similar results of the association
between serum irisin and CKD as those in Table 3 (data
not shown).Discussion
Obesity has become a worldwide epidemic, and the
prevalence of obesity-related health conditions, such as
insulin resistance, metabolic syndrome, type 2 diabetes,
hypertension, cardiovascular disease, cancer and chronic
kidney disease, increased significantly [9,10]. Physical ex-
ercise, as a lifestyle intervention approach, has long been
recognized for its effects on these obesity-related comor-
bidities, although the underlying mechanisms remain to
be fully understood [32]. Irisin was identified in 2012 by
Boström as a putative exercise induced myokine, which
drives brown-fat-like conversion of white adipose tissues,
has broad implications for metabolism and energy
homeostasis [13,15]. Circulating irisin has been found to
be reduced in nonalcoholic fatty liver disease (NAFLD)
[27] and type 2 diabetes patients compared with their
controls [15-17]. Because NAFLD, type 2 diabetes and
CKD share the same pathology of obesity and insulin
Table 2 Demographic, lifestyle and clinical characteristics of subjects by tertiles of irisin
Variables Quartile 1 Quartile 2 Quartile 3 Quartile 4 Total P value
Irisin (ng/mL) 0.13 (0.02, 1.56) 4.73 (3.83, 5.97) 10.38 (8.67, 12.17) 23.05 (17.73, 31.28) 7.26 (2.75, 14.72) <0.001‡
Demographics
N (%) 279 (25.0%) 279 (25.0%) 279 (25.0%) 278 (25.0%) 1115 (100.0%)
Sex
Male (n, %) 94 (33.7%) 100 (35.8%) 85 (30.5%) 70 (25.2%) 349 (31.3%) 0.039*
Female (n, %) 185 (66.3%) 179 (64.2%) 194 (69.5%) 208 (74.8%) 766 (68.7%)
Age (years) 53.2 ± 7.4 52.6 ± 7.4 53.4 ± 7.1 53.5 ± 7.0 53.2 ± 7.2 0.7
Education categories, (n, %) 0.4
Illiteracy 66 (23.7%) 70 (25.1%) 91 (32.6%) 75 (27.0%) 302 (27.1%)
Elementary school 87 (31.2%) 77 (27.6%) 77 (27.6%) 89 (32.0%) 330 (29.6%)
Middle school 67 (24.0%) 77 (27.6%) 52 (18.6%) 60 (21.6%) 256 (23.0%)
High school 35 (12.5%) 33 (11.8%) 38 (13.6%) 36 (13.0%) 142 (12.7%)
College or above 24 (8.6%) 22 (7.9%) 21 (7.5%) 18 (6.4%) 85 (7.6%)
Life style
Ever smoking (n, %) 82 (29.4%) 81 (29.0%) 73 (26.2%) 59 (21.2%) 295 (26.5%) 0.1
Ever drinking (n, %) 37 (13.3%) 27 (9.7%) 36 (12.9%) 30 (10.8%) 130 (11.7%) 0.4
Physical activity (MET-h/week) 84.0 (46.2, 158.2) 84.0 (46.2, 140.0) 87.3 (46.2, 152.4) 100.3 (56.0, 154.0) 84.0 (51.6, 148.4) 0.4
Body composition indices
BMI (kg/m2) 27.5 ± 3.1 27.3 ± 3.1 27.7 ± 3.3 27.2 ± 2.8 27.5 ± 3.1 0.2
Waist circumference (cm) 94.1 ± 7.3 93.8 ± 7.2 93.4 ± 7.1 93.1 ± 6.6 93.6 ± 7.1 0.4
Waist hip ratio 0.940 ± 0.049 0.943 ± 0.050 0.933 ± 0.050 0.930 ± 0.049 0.937 ± 0.049 0.006†
Body fat mass (kg) 24.0 ± 5.4 23.3 ± 5.3 24.1 ± 5.6 24.0 ± 5.1 23.9 ± 5.3 0.2
Body fat rate (%) 34.6 ± 6.6 34.0 ± 6.9 35.1 ± 7.0 35.3 ± 6.3 34.7 ± 6.7 0.1
Body fat free weight (kg) 46.7 ± 9.2 46.2 ± 8.4 45.8 ± 8.5 44.8 ± 7.5 45.9 ± 8.4 0.1
Muscle mass (kg) 44.1 ± 8.8 43.7 ± 8.1 43.2 ± 8.1 42.2 ± 7.2 43.3 ± 8.1 0.048*
Clinical characteristics
Systolic blood pressure (mmHg) 133.9 ± 17.5 133.1 ± 17.6 135.7 ± 20.1 133.1 ± 16.0 134.0 ± 17.9 0.3
Diastolic blood pressure (mmHg) 80.1 ± 10.7 80.0 ± 10.8 80.4 ± 12.1 79.0 ± 9.6 79.9 ± 10.8 0.4
Serum albumin (g/L) 49.1 ± 2.4 48.9 ± 2.4 49.0 ± 2.3 49.2 ± 2.5 49.0 ± 2.5 0.8
Serum glubulin (g/L) 25.0 ± 3.2 25.7 ± 3.4 26.5 ± 3.7 26.8 ± 3.4 26.0 ± 3.4 <0.001‡
Triglyceride (mmol/L) 1.94 ± 1.44 1.98 ± 1.34 1.81 ± 1.16 1.77 ± 1.15 1.87 ± 1.28 0.2
Total cholesterol (mmol/L) 5.83 ± 1.10 5.77 ± 1.00 5.91 ± 1.11 5.95 ± 1.13 5.87 ± 1.09 0.2
HDL-cholesterol (mmol/L) 1.36 ± 0.30 1.35 ± 0.31 1.36 ± 0.28 1.39 ± 0.30 1.37 ± 0.30 0.6
LDL-cholesterol (mmol/L) 3.59 ± 1.02 3.54 ± 0.96 3.73 ± 1.03 3.76 ± 1.03 3.65 ± 1.01 0.022*
Fasting glucose (mmol/L) 6.22 ± 1.95 6.09 ± 1.69 6.23 ± 1.95 6.09 ± 1.35 6.16 ± 1.75 0.6
Glucose 120 min OGTT (mmol/L) 9.11 ± 4.17 8.93 ± 4.09 9.16 ± 4.24 9.01 ± 3.90 9.05 ± 4.10 0.9
Fasting insulin (mIU/L) 13.2 ± 7.2 12.6 ± 6.8 12.5 ± 6.4 12.7 ± 6.6 12.7 ± 6.8 0.6
HOMA-IR (*10-6 mol*IU*L-2) 3.68 ± 2.37 3.49 ± 2.59 3.51 ± 2.22 3.50 ± 2.21 3.54 ± 2.35 0.7
HbA1c 6.27 ± 1.25 6.17 ± 0.97 6.23 ± 1.06 6.16 ± 0.85 6.21 ± 1.04 0.6
Hyperuricemia, (n (%)) 120 (43.0%) 103 (36.9%) 104 (37.3%) 103 (37.1%) 430 (38.6%) 0.4
eGFR <60 mL/min/1.73 m2, (n (%)) 9 (3.2%) 13 (4.7%) 11 (3.9%) 7 (2.5%) 40 (3.6%) 0.6
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Table 3 Adjusted odds ratios (ORs) with associated 95% confidence interval (CI) for reduced renal function,
albuminuira and CKD
Reduced renal function Albuminuira CKD
Variables OR 95% CI P value OR 95% CI P value OR 95% CI P value
Model 1
BMI (kg/m2) 1.073 0.971-1.186 0.2 1.09 1.047-1.148 <0.001* 1.098 1.050-1.149 <0.001*
Waist circumference (cm) 0.995 0.947-1.045 0.8 1.039 1.018-1.061 <0.001* 1.031 1.011-1.052 0.003*
Body fat mass (kg) 1.084 1.023-1.150 0.007* 1.049 1.018-1.080 0.002* 1.055 1.026-1.086 <0.001*
Body fat rate (%) 1.083 1.004-1.167 0.038* 1.082 1.043-1.121 <0.001* 1.085 1.048-1.124 <0.001*
Serum irisin† 0.987 0.721-1.353 0.9 0.948 0.820-1.096 0.5 0.949 0.826-1.091 0.5
Serum irisin
(Quartile 2 vs. Quartile 1) 1.616 0.669-3.906 0.3 0.926 0.605-1.416 0.7 1.007 0.671-1.511 1.0
(Quartile 3 vs. Quartile 1) 1.228 0.493-3.057 0.7 1.287 0.859-1.926 0.2 1.340 0.908-1.979 0.1
(Quartile 4 vs. Quartile 1) 0.766 0.278-2.110 0.6 0.740 0.479-1.141 0.2 0.721 0.474-1.096 0.1
Model 2
BMI (kg/m2) 1.074 0.958-1.205 0.2 1.100 1.046-1.156 <0.001* 1.102 1.049-1.158 <0.001*
Waist circumference (cm) 1.011 0.959-1.066 0.7 1.038 1.015-1.061 0.001* 1.034 1.011-1.057 0.003*
Body fat mass (kg) 1.093 1.020-1.172 0.012* 1.053 1.019-1.087 0.002* 1.059 1.026-1.093 <0.001*
Body fat rate (%) 1.088 1.000-1.183 0.1 1.083 1.042-1.125 <0.001* 1.087 1.047-1.129 <0.001*
Serum irisin † 0.992 0.697-1.412 1.0 0.914 0.784-1.066 0.3 0.917 0.859-1.379 0.3
Serum irisin
(Quartile 2 vs. Quartile 1) 1.738 0.640-4.722 0.3 0.760 0.477-1.209 0.2 0.848 0.542-1.326 0.5
(Quartile 3 vs. Quartile 1) 1.334 0.471-3.780 0.6 1.106 0.711-1.719 0.7 1.191 0.775-1.831 0.4
(Quartile 4 vs. Quartile 1) 0.607 0.183-2.008 0.4 0.641 0.401-1.024 0.1 0.620 .392-0.980 0.041*
Model 3
BMI (kg/m2) 1.031 0.910-1.167 0.6 1.053 0.996-1.113 0.1 1.052 0.996-1.110 0.1
Waist circumference (cm) 0.997 0.945-1.053 0.9 1.023 0.998-1.048 0.1 1.017 0.993-1.041 0.2
Body fat mass (kg) 1.076 0.999-1.159 0.1 1.034 0.998-1.071 0.1 1.039 1.004-1.076 0.029*
Body fat rate (%) 1.062 0.969-1.164 0.2 1.046 1.002-1.092 0.039* 1.049 1.006-1.093 0.025*
Serum irisin† 0.946 0.660-1.357 0.8 0.910 0.771-1.073 0.3 0.906 0.772-1.064 0.2
Serum irisin
(Quartile 2 vs. Quartile 1) 1.609 0.579-4.472 0.4 0.786 0.485-1.272 0.3 0.873 0.549-1.388 0.6
(Quartile 3 vs. Quartile 1) 1.185 0.407-3.448 0.8 1.050 0.658-1.673 0.8 1.123 0.713-1.769 0.6
(Quartile 4 vs. Quartile 1) 0.507 0.147-1.746 0.3 0.611 0.373-1.000 0.050* 0.572 0.353-0.927 0.023*
*p < 0.05.
†OR and 95% CI was impressed as per SD increase of log transformed serum irisin.
Abbreviations: BMI body mass index, CKD chornic kidney disease.
Model 1 was adjusted for sex and age;
Model 2 was further adjusted for educational level, ever smoking, ever drinking and physical activity.
Model 3 was further adjusted for SBP, DBP, serum glubulin, hyperuricemia,TG,LDL, fasting glucose.
Table 2 Demographic, lifestyle and clinical characteristics of subjects by tertiles of irisin (Continued)
Albumin creatinine ratio > =30 mg/g, (n (%)) 57 (20.4%) 52 (18.6%) 70 (25.1%) 47 (16.9%) 226 (20.3%) 0.1
CKD, (n (%)) 64 (22.9%) 62 (22.2%) 80 (28.7%) 52 (18.7%) 258 (23.1%) 0.046*
*p < 0.05, †p < 0.01, ‡p < 0.001.
All percentages are column percentage; except for percentages, all values are mean ± s.d. or median(25th, 75th) for non-normal distribution data.
Abbreviations: ACR albumin creatinine ratio, BMI body mass index, CKD chornic kidney disease, eGFR estimated glomerular filtration rate, HDL high-density
lipoprotein cholesterol, HOMA-IR homeostasis model assessment insulin resistance index, LDL low-density lipoprotein cholesterol, MET-h/week metabolic
equivalent hours per week.
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irisin level was negatively associated with risk of CKD.
Wen and co-workers first found that plasma irisin
levels were significantly decreased in 38 CKD patients
compared to 19 age- and sex-matched normal controls,
but they failed to find independent association of irisin
with CKD [18]. Liu found that circulating irisin was sig-
nificantly decreased in 179 T2DM patients with renal in-
sufficiency (eGFR < 60 ml/min/1.73 m2) compared to
186 T2DM patients with normal renal function (eGFR ≥
60 ml/min/1.73 m2); and the reduction in irisin was
most pronounced in stage 5 CKD patients [19]. In the
multivariate linear regression model, Liu found that cir-
culating irisin was independently associated with GFR
but failed to observe association of circulating irisin with
early markers of kidney injury such as microalbuminuria
[19]. In 532 patients with stages 1–5 of CKD, Ebert
found that irisin serum concentrations decreased with
increasing CKD stage and are independently and posi-
tively predicted by renal function in robust multivariate
analysis [20]. However, several major limitations dimin-
ished the value of these studies, such as the relatively
small sample sizes and including only CKD patients or
T2DM patients. Larger studies with different popula-
tions are awaited to validate the associations of serum
irisin concentration with CKD.
In the present study, we found that, compared to those
with the lowest serum irisin (quartile 1 group), subjects
with the highest (quartile 4 group) had significantly the
lowest prevalence of CKD. In multivariable logistic re-
gression model with adjustment for potential con-
founders, compared with those within quartile 1 group
of serum irisin, subjects within quartile 4 group showed
significantly decreased risk of CKD and marginally de-
creased risk of albuminuria, although subjects in quartile
2–3 groups failed to show similar trend. Therefore, fur-
ther studies on the association between serum irisin and
CKD with larger sample size from different populations,
especially from the prospective cohort studies are
warranted.
Mechanisms underlying the association between
serum irisin and decreased risk of CKD are not fully
understood. Firstly, some suggest that CKD is character-
ized by progressive muscle wasting and reduced muscle
mass may partially account for reduced irisin expression
and secretion. However, in our previous paper, we did
not find a positive relationship between serum irisin and
body muscle mass [26]. Furthermore, in the multivari-
able logistic regression model in the present study,
muscle mass was adjusted for as a potential confounder.
So it seems our results do not support this hypothesis.
Secondly, insulin resistance and hyperglycemia play im-
portant roles in patients with CKD [33]. In our previous
paper, we found that fasting insulin and HbA1c werenegatively associated with serum irisin level in stepwise
multivariable linear regression analysis [26]. Therefore,
our results seem to support the hypothesis that irisin
improves insulin resistance and glucose homeostasis and
then reduces the risk of CKD. Our results may have clin-
ical implication of the therapeutic potential of irisin for
CKD if further studies, especially from prospective co-
hort studies and intervention studies, clearly demon-
strate the protective effect of irisin on CKD.
Numerous previous studies have found that obesity is
independently associated with increased risk of CKD,
and body mass index (BMI) has been widely used as the
index of obesity in these studies [1-3,5-7]. However,
there are still many studies which have shown that BMI
and other measures of adiposity, such as waist circum-
ference, body fat percentage, have different associations
with various health conditions [21-23]. Furthermore, re-
cent studies show that irisin is not only a myokine but
also an adipokine, both muscle and adipose tissue con-
tribute to circulating irisin [24,25]. These two points
prompt us to test the independent association of differ-
ent body composition measurements with CKD. And we
found that only body fat percentage, but not BMI or
waist circumference, was independently associated with
CKD after adjusting for potential confounders. Our re-
sults suggest that adiposity per se, rather than body
weight or body shape, is independently associated with
increased risk factor of CKD. Therefore, more studies
are warranted to test the independent association of dif-
ferent measures of body composition with CKD in dif-
ferent populations.
China, a developing country with a relatively high eco-
nomic development speed within the past three decades,
is facing the increasing prevalence of obesity and associ-
ated health conditions, such as cardiovascular disease,
diabetes and CKD. Although the prevalence of CKD in
China has been reported to be around 10% [5-7], little
evidence is available on the prevalence of CKD in obese
Chinese adults. The present study found that, for the
obese healthy Chinese adults, the prevalence rates (95%
CI) of CKD were 26.6% (23.2%-29.4%) in females and
15.5% (11.8%-19.2%) in males, which were much higher
than those of the general adults in China. We also found
that the prevalence of albuminuria (23.8% in females
and 12.6% in males) was much higher than those of gen-
eral Chinese adults (6%-9%) [5-7]. Therefore, for the
obese adults in China, even they may look generally
healthy, screening for CKD, especially albuminuria,
should attract attention not only for heath workers but
also for obese subjects themselves.
Several limitations of the present study need to be rec-
ognized. First, the present subjects were not randomly
sampled from their living communities and were gener-
ally healthy without any previously diagnosed common
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eases were underrepresented in the present study; so
there were some kinds of “healthy volunteer bias” in the
present study, and we might under-estimate the preva-
lence of CKD in the general obese adults. Therefore, the
present sample was not as good as that which was ran-
domly sampled from the general community-living sub-
jects to estimate the prevalence of CKD. Second, we are
not certain about the temporal sequence between serum
irisin and CKD because of the cross-sectional study de-
sign. Therefore, our results should be confirmed in fu-
ture prospective cohort studies and intervention studies.
Third, all subjects recruited into the present study are
central obese adults, which may hamper us to extrapo-
late our findings to the non-obese adults. Last but not
least, we did not measure other cytokines, such as adipo-
nectin, IL-6 and TNF-α, which may be related to serum
irisin. On the other hand, our study has a lot of
strengths. Firstly, our study has a relatively large sample
size of obese adults. And we have also adjusted for much
more potential confounders than previous studies. For
example, few previous studies adjusted for physical activ-
ity, body fat and muscle mass, which were important
confounding factors of serum irisin.Conclusions
Our study found that subjects with the highest serum iri-
sin (quartile 4 group) had significantly decreased risk of
CKD and marginally decreased risk of albuminuria. Future
works about the association of serum irisin with CKD, es-
pecially from prospective cohort studies with larger sam-
ple size, are warranted. In addition, we also found only
body fat percentage, neither BMI nor waist circumference,
was independently associated with increased risk of CKD,
which suggests that it is adiposity per se, rather than body
weight or body shape, is independently associated with in-
creased risk of CKD. Therefore, decreasing body fat per-
centage should be emphasized for the obese adults. Third,
the prevalence of CKD in obese adults was much higher
than that of the general adults in China; of which the
prevalence of albuminuria was about two or three times of
those general adults. Therefore, screening for CKD, espe-
cially albuminuria, in the obese adults, should attract at-
tention not only for heath workers but also for obese
subjects themselves.Abbreviations
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